NEWS & MEDIA

News & Events

BD Announces Record Revenues for Fiscal Second Quarter

Company Reaffirms Outlook for full Year

Franklin Lakes, NJ (April 18, 2001) -- BD (Becton, Dickinson and Company) (NYSE:BDX) today announced revenues of $961 million for the second quarter ended March 31, 2001, the largest quarterly revenues reported in the history of the Company.

Reported revenues for the quarter represented an increase of 4 percent over the same period a year ago. Revenues were affected by foreign currency translation, related primarily to the Euro and Japanese Yen, which reduced revenues by an estimated 3 percent.

Diluted earnings per share for the quarter were 44 cents, compared with 45 cents for the prior year’s quarter. The prior year’s reported earnings per share included a gain on the sale of an equity investment offset in part by the unfavorable impact of a voluntary product recall. Excluding these items, earnings per share for the prior year would have been 42 cents.

“We are pleased with our revenue growth, which was driven by U.S. sales of advanced protection devices and from strong sales in our Biosciences segment,” said Edward J. Ludwig, president and chief executive officer. “The growth in sales of our advanced protection devices reflects our effectiveness in converting the U.S. market to the adoption of new devices engineered to provide added protection for healthcare workers.”

Commenting on the Company’s outlook, Mr. Ludwig noted, “For fiscal 2001, we continue to expect year-on-year net income growth to be double digit, with expected earnings per share of approximately 46 cents in the third quarter and $1.63 for the full year.”

Q2 Segment Results
As previously announced, beginning October 1, 2000, the Company revised its reporting segments. The microbiology product line (now known as diagnostic systems) was moved from the Biosciences segment and combined with the segment formerly known as Preanalytical Solutions to form the Clinical Laboratory Solutions segment. Summary revenue data reflecting the revised segments are as follows:

Revenues by Segment ($ in millions)	Second Fiscal Quarter		Six Months Ended March 31
	2001	2000	2001	2000
Medical Systems	$507	$489	$945	$952
Clinical Laboratory Solutions	298	294*	575	565*
Biosciences	156	142*	284	267*
Total	$961	$925	$1,804	$1,784

* Restated Clinical Laboratory Solutions revenues for the three months and six months ended March 31, 2000 include, respectively, $139 million and $272 million related to the former Preanalytical Solutions segment, and $154 million and $293 million related to the microbiology product group that previously had been included in Biosciences revenues.

In the Medical Systems segment, worldwide revenues of $507 million increased 4 percent for the quarter, or 7 percent at constant foreign exchange rates. In the Clinical Laboratory Solutions segment, worldwide revenues increased 2 percent to $298 million, or 5 percent at constant foreign exchange rates. Both segments benefited from strong sales of advanced protection devices. U.S. sales of safety-engineered products were $58 million for Medical Systems, representing an increase of 53 percent versus the prior year’s quarter, and $38 million for Clinical Laboratory Solutions, representing an increase of 44 percent versus the prior year’s quarter.

Revenues for the Biosciences segment grew 10 percent to $156 million. At constant foreign exchange rates, revenues increased 14 percent. All product groups contributed to this growth.

Q2 Geographic Results
On a geographic basis, second quarter revenues in the United States increased 6 percent to $511 million. Revenues outside the United States of $451 million increased 2 percent, or 9 percent at constant foreign exchange rates.

Six-Month Results
For the six-month period ended March 31, 2001, reported revenues were $1.804 billion, a 1 percent increase over $1.784 billion a year ago, or 5 percent at constant foreign exchange rates. Diluted earnings per share for the six-month period were 67 cents. For the same period in fiscal 2000, diluted earnings per share were 74 cents, which included the items in the second quarter referred to above.

BD is a medical technology company that manufactures and sells a broad range of supplies, devices and systems for use by healthcare professionals, medical research institutions, industry and the general public.

###

BD’s news releases can be found on its website at www.bd.com or through Business Wire at www.businesswire.com. A conference call with analysts regarding this news release will be broadcast live on BD’s website at 8:30 a.m. EDT Thursday, April 19, 2001, and will be available for playback through April 25, 2001. The conference call will be recorded for playback at 1-800-391-9847.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

                                         Three Months Ended March 31,
                                         2001        2000     % Change
----------------------------------------------------------------------

REVENUES                      $      961,179   $    925,132       3.9

Cost of products sold                487,615        473,987       2.9
Selling and administrative           241,912        244,063      (0.9)
Research and development              54,497         57,175      (4.7)
----------------------------------------------------------------------
TOTAL OPERATING COSTS                                      
     AND EXPENSES                    784,024        775,225       1.1
----------------------------------------------------------------------
OPERATING INCOME                     177,155        149,907      18.2

Interest expense, net                (15,998)       (21,199)    (24.5)
Other (expense) income, net           (5,418)        36,399        NM
----------------------------------------------------------------------
INCOME BEFORE                                              
     INCOME TAXES                     155,739       165,107      (5.7)

Income tax provision                   37,377        45,936     (18.6)
----------------------------------------------------------------------
NET INCOME                     $      118,362   $   119,171      (0.7)
----------------------------------------------------------------------
EARNINGS PER SHARE

     Basic                     $         0.46   $      0.47      (2.1)
     Diluted                   $         0.44   $      0.45      (2.2)
----------------------------------------------------------------------
AVERAGE SHARES OUTSTANDING

     Basic                            257,021       252,055
     Diluted                          269,172       263,376
----------------------------------------------------------------------
NM - Not Meaningful                            



BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

                                        Six Months Ended March 31,
                                     2001            2000     % Change
----------------------------------------------------------------------
REVENUES                     $    1,804,436  $    1,784,296       1.1

Cost of products sold               936,562         923,938       1.4
Selling and administrative          477,204         477,901      (0.1)
Research and development            107,224         110,918      (3.3)
----------------------------------------------------------------------
TOTAL OPERATING COSTS                                        
     AND EXPENSES                 1,520,990       1,512,757       0.5
----------------------------------------------------------------------
OPERATING INCOME                    283,446         271,539       4.4

Interest expense, net               (34,562)        (42,756)    (19.2)
Other (expense) income, net         (13,379)         38,073        NM
----------------------------------------------------------------------
INCOME BEFORE
   INCOME TAXES                     235,505         266,856     (11.7)

Income tax provision                 56,521          72,391     (21.9)
----------------------------------------------------------------------
NET INCOME                   $      178,984  $      194,465      (8.0)
----------------------------------------------------------------------
EARNINGS PER SHARE

     Basic                   $         0.69  $         0.77     (10.4)
     Diluted                 $         0.67  $         0.74      (9.5)
----------------------------------------------------------------------
AVERAGE SHARES OUTSTANDING

     Basic                          255,729         251,690
     Diluted                        267,806         262,986
----------------------------------------------------------------------
NM - Not Meaningful


BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
(Unaudited; Amounts in thousands)

                                         Three Months Ended March 31,
                                         2001          2000   % Change
----------------------------------------------------------------------
MEDICAL SYSTEMS
---------------
   United States                 $     250,942  $     232,003     8.2
   International                       255,896        257,326    (0.6)
----------------------------------------------------------------------
TOTAL                            $     506,838  $     489,329     3.6
----------------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
-----------------------------
   United States                 $     175,725  $     172,427     1.9
   International                       122,634        121,506     0.9
----------------------------------------------------------------------
TOTAL                            $     298,359  $     293,933     1.5
----------------------------------------------------------------------
BIOSCIENCES
-----------
   United States                 $      83,905  $      77,309     8.5
   International                        72,077         64,561    11.6
----------------------------------------------------------------------
TOTAL                            $     155,982  $     141,870     9.9
----------------------------------------------------------------------
TOTAL REVENUES
--------------
   United States                 $     510,572  $     481,739     6.0
   International                       450,607        443,393     1.6
----------------------------------------------------------------------
TOTAL                            $     961,179  $     925,132     3.9
----------------------------------------------------------------------

                                         Six Months Ended March 31,
                                         2001          2000   % Change
                                 -------------------------------------

MEDICAL SYSTEMS
---------------
   United States                 $     452,961  $     438,625     3.3
   International                       492,311        513,310    (4.1)
----------------------------------------------------------------------
TOTAL                            $     945,272  $     951,935    (0.7)
----------------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
-----------------------------
   United States                 $     335,404  $     320,950     4.5
   International                       239,908        244,082    (1.7)
----------------------------------------------------------------------
TOTAL                            $     575,312  $     565,032     1.8
----------------------------------------------------------------------
BIOSCIENCES
-----------
   United States                 $     153,491  $     148,623     3.3
   International                       130,361        118,706     9.8
----------------------------------------------------------------------
TOTAL                            $     283,852  $     267,329     6.2
----------------------------------------------------------------------
TOTAL REVENUES
--------------
   United States                 $     941,856  $     908,198     3.7
   International                       862,580        876,098    (1.5)
----------------------------------------------------------------------
TOTAL                            $   1,804,436  $   1,784,296     1.1
----------------------------------------------------------------------

BECTON DICKINSON AND COMPANY
REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
THREE MONTHS ENDED MARCH 31,
(Unaudited; Amounts in thousands)

                                                United States
                                 -------------------------------------
                                         2001          2000   % Change
                                 -------------------------------------

MEDICAL SYSTEMS
---------------
   Core Medical                  $     152,165  $     138,673     9.7
   Consumer Health Care                 79,135         75,624     4.6
   Pharmaceutical Systems               12,422         11,190    11.0
   Ophthalmic Systems                    7,220          6,516    10.8
----------------------------------------------------------------------
TOTAL                            $     250,942  $     232,003     8.2
----------------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
-----------------------------
   Preanalytical Solutions       $      86,489  $      78,406    10.3
   Diagnostic Systems                   89,236         94,021    (5.1)
----------------------------------------------------------------------
TOTAL                            $     175,725  $     172,427     1.9
----------------------------------------------------------------------
BIOSCIENCES
-----------
   Immunocytometry & Reagents    $      60,332  $      57,100     5.7
   Discovery Labware                    23,573         20,209    16.6
----------------------------------------------------------------------
TOTAL                            $      83,905  $      77,309     8.5
----------------------------------------------------------------------
TOTAL UNITED STATES              $     510,572  $     481,739     6.0
----------------------------------------------------------------------

                                              International
                                 -------------------------------------
                                         2001         2000    % Change
                                 -------------------------------------

MEDICAL SYSTEMS
---------------
   Core Medical                  $      144,842  $    150,591    (3.8)
   Consumer Health Care                  48,277        50,524    (4.4)
   Pharmaceutical Systems                56,601        50,700    11.6
   Ophthalmic Systems                     6,176         5,511    12.1
----------------------------------------------------------------------
TOTAL                            $      255,896  $    257,326    (0.6)
----------------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
-----------------------------
   Preanalytical Solutions       $       62,657  $     61,080     2.6
   Diagnostic Systems                    59,977        60,426    (0.7)
----------------------------------------------------------------------
TOTAL                            $      122,634  $    121,506     0.9
----------------------------------------------------------------------
BIOSCIENCES
-----------
   Immunocytometry & Reagents    $       56,045  $     48,723    15.0
   Discovery Labware                     16,032        15,838     1.2
----------------------------------------------------------------------
TOTAL                            $       72,077  $     64,561    11.6
----------------------------------------------------------------------
TOTAL INTERNATIONAL              $      450,607  $    443,393     1.6
----------------------------------------------------------------------

                                                  Total
                                 -------------------------------------
                                         2001          2000   % Change
                                 -------------------------------------

MEDICAL SYSTEMS
---------------
   Core Medical                  $     297,007  $     289,264     2.7
   Consumer Health Care                127,412        126,148     1.0
   Pharmaceutical Systems               69,023         61,890    11.5
   Ophthalmic Systems                   13,396         12,027    11.4
----------------------------------------------------------------------
TOTAL                            $     506,838  $     489,329     3.6
----------------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
-----------------------------
   Preanalytical Solutions       $     149,146  $     139,486     6.9
   Diagnostic Systems                  149,213        154,447    (3.4)
----------------------------------------------------------------------
TOTAL                            $     298,359  $     293,933     1.5
----------------------------------------------------------------------
BIOSCIENCES
-----------
   Immunocytometry & Reagents    $     116,377  $     105,823    10.0
   Discovery Labware                    39,605         36,047     9.9
----------------------------------------------------------------------
TOTAL                            $     155,982  $     141,870     9.9
----------------------------------------------------------------------
TOTAL REVENUES                   $     961,179  $     925,132     3.9
----------------------------------------------------------------------

                                          FX Neutral % Growth        
                                    -------------------------------
                                      International      Total
                                    --------------- ---------------

MEDICAL SYSTEMS
---------------
   Core Medical                             1.8             5.6
   Consumer Health Care                     1.8             3.5
   Pharmaceutical Systems                  21.3            19.4
   Ophthalmic Systems                      20.8            15.4
----------------------------------------------------------------------
TOTAL                                       6.0             7.0
----------------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
-----------------------------
   Preanalytical Solutions                 10.2            10.3
   Diagnostic Systems                       5.9            (0.8)
----------------------------------------------------------------------
TOTAL                                       8.1             4.5
----------------------------------------------------------------------
BIOSCIENCES
-----------
   Immunocytometry & Reagents              23.4            13.8
   Discovery Labware                        8.5            13.1
----------------------------------------------------------------------
TOTAL                                      19.7            13.6
----------------------------------------------------------------------

TOTAL                                       8.6             7.2
----------------------------------------------------------------------


BECTON DICKINSON AND COMPANY
REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
SIX MONTHS ENDED MARCH 31,
(Unaudited; Amounts in thousands)

                                               United States
                                 -------------------------------------
                                         2001          2000   % Change
                                 -------------------------------------

MEDICAL SYSTEMS
---------------
   Core Medical                  $     292,205  $     273,582     6.8
   Consumer Health Care                123,636        131,257    (5.8)
   Pharmaceutical Systems               22,692         19,808    14.6
   Ophthalmic Systems                   14,428         13,978     3.2
----------------------------------------------------------------------
TOTAL                            $     452,961  $     438,625     3.3
----------------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
-----------------------------
   Preanalytical Solutions       $     163,069  $     147,477    10.6
   Diagnostic Systems                  172,335        173,473    (0.7)
----------------------------------------------------------------------
TOTAL                            $     335,404  $     320,950     4.5
----------------------------------------------------------------------
BIOSCIENCES
-----------
   Immunocytometry & Reagents    $     111,826  $     110,428     1.3
   Discovery Labware                    41,665         38,195     9.1
----------------------------------------------------------------------
TOTAL                            $     153,491  $     148,623     3.3
----------------------------------------------------------------------
TOTAL UNITED STATES              $     941,856  $     908,198     3.7
----------------------------------------------------------------------

                                              International
                                 -------------------------------------
                                        2001          2000    % Change
                                 -------------------------------------

MEDICAL SYSTEMS
---------------
   Core Medical                  $     281,678  $    301,848     (6.7)
   Consumer Health Care                 96,183        99,411     (3.2)
   Pharmaceutical Systems              103,322       101,373      1.9
   Ophthalmic Systems                   11,128        10,678      4.2
----------------------------------------------------------------------
TOTAL                            $     492,311  $    513,310     (4.1)
----------------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
-----------------------------
   Preanalytical Solutions       $     119,701  $    124,151     (3.6)
   Diagnostic Systems                  120,207       119,931      0.2
----------------------------------------------------------------------
TOTAL                            $     239,908  $    244,082     (1.7)
----------------------------------------------------------------------
BIOSCIENCES
-----------
   Immunocytometry & Reagents    $      99,884  $     87,907     13.6
   Discovery Labware                    30,477        30,799     (1.0)
----------------------------------------------------------------------
TOTAL                            $     130,361  $    118,706      9.8
----------------------------------------------------------------------
TOTAL INTERNATIONAL              $     862,580  $    876,098     (1.5)
----------------------------------------------------------------------

                                                  Total
                                 -------------------------------------
                                         2001          2000   % Change
                                 -------------------------------------

MEDICAL SYSTEMS
---------------
   Core Medical                  $     573,883  $     575,430    (0.3)
   Consumer Health Care                219,819        230,668    (4.7)
   Pharmaceutical Systems              126,014        121,181     4.0
   Ophthalmic Systems                   25,556         24,656     3.7
----------------------------------------------------------------------
TOTAL                            $     945,272  $     951,935    (0.7)
----------------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
-----------------------------
   Preanalytical Solutions       $     282,770  $     271,628     4.1
   Diagnostic Systems                  292,542        293,404    (0.3)
----------------------------------------------------------------------
TOTAL                            $     575,312  $     565,032     1.8
----------------------------------------------------------------------
BIOSCIENCES
-----------
   Immunocytometry & Reagents    $     211,710  $     198,335     6.7
   Discovery Labware                    72,142         68,994     4.6
----------------------------------------------------------------------
TOTAL                            $     283,852  $     267,329     6.2
----------------------------------------------------------------------
TOTAL REVENUES                   $   1,804,436  $   1,784,296     1.1
----------------------------------------------------------------------

                                          FX Neutral % Growth
                                    -------------------------------
                                      International       Total
                                    --------------- ---------------

MEDICAL SYSTEMS
---------------
   Core Medical                            (0.1)            3.2
   Consumer Health Care                     5.2            (1.0)
   Pharmaceutical Systems                  15.2            15.1
   Ophthalmic Systems                      14.5             8.1
----------------------------------------------------------------------
TOTAL                                       4.3             3.8
----------------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
-----------------------------
   Preanalytical Solutions                  5.4             8.2
   Diagnostic Systems                       8.1             2.9
----------------------------------------------------------------------
TOTAL                                       6.7             5.5
----------------------------------------------------------------------
BIOSCIENCES
-----------
   Immunocytometry & Reagents              25.5            12.0
   Discovery Labware                        7.2             8.3
----------------------------------------------------------------------
TOTAL                                      20.7            11.0
----------------------------------------------------------------------

TOTAL                                       7.2             5.4
----------------------------------------------------------------------

This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding the company's performance, including future revenues, products and income, or events or developments that the company expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of the company and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to, competitive factors, changes in regional, national or foreign economic conditions, changes in interest or foreign currency exchange rates, delays in product introductions, and changes in healthcare or other governmental regulation, as well as other factors discussed herein and in the company's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements.